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Introduction {#sec001}
============

It is well established that ZIKV infection in pregnant women may lead to severe neurological consequences, such as microcephaly in newborns \[[@pntd.0008413.ref001]--[@pntd.0008413.ref005]\]. Clinical and animal studies have shown that miscarriage and brain malformation are more frequent when infection occurs early during pregnancy \[[@pntd.0008413.ref001]--[@pntd.0008413.ref010]\]. ZIKV-associated microcephaly is most likely due to the high susceptibility of neural stem/progenitor cells (NS/PCs), which populate and develop the fetal brain, to ZIKV infection \[[@pntd.0008413.ref011]--[@pntd.0008413.ref014]\]. Nevertheless, how ZIKV gains access to the fetal brain and why earlier infection has more severe outcomes have not been fully elucidated.

Microglia are the first-line defenders against infections in the brain \[[@pntd.0008413.ref015]--[@pntd.0008413.ref017]\]. They originate exclusively from the erythro-myeloid progenitors in the YS and migrate to the embryonic brain during early development \[[@pntd.0008413.ref018]\]. A previous study demonstrated that a flavivirus entry factor Axl renders human fetal brain microglia permissive to ZIKV infection \[[@pntd.0008413.ref019]\]. In a human induced pluripotent stem cell (hiPSC)-derived human macrophage/microglia and NS/PC co-culture system, ZIKV-infected macrophages/microglia are able to transmit the virus to NS/PCs and induce apoptosis \[[@pntd.0008413.ref020]\]. However, it is unknown whether YS microglia progenitor cells are susceptible to ZIKV infection. Two research groups have hypothesized that microglia may act as a "Trojan horse" by disseminating Toxoplasma gondii (one of the TORCH agents causing human microcephaly) and bovine viral diarrhea virus (another flavivirus causing congenital infection and fetal demise in cattle) into the brain during invasion \[[@pntd.0008413.ref021], [@pntd.0008413.ref022]\]. In this study, we determined the role of YS-derived microglial progenitors in a mouse model of vertical ZIKV transmission.

Methods {#sec002}
=======

Mice {#sec003}
----

This study was conducted at the University of Texas Medical Branch, and was reviewed and approved by the Institutional Animal Care and Use Committee of University of Texas Medical Branch (approval 1008041C). All procedures followed the National Institutes of Health Guide for the Care and Use of Laboratory Animals. IFNAR1^-/-^ female mice (8- to 11-week-old) were crossed to C57BL/6J male mice \[[@pntd.0008413.ref023]\], and housed in a specific-pathogen-free facility. Timed matings were set up, and the presence of a vaginal plug in the breeding female was designated as gestational age E0.5. Pregnant dams were infected subcutaneously with 10^4^ PFU ZIKV at E6.5-E8.5, E9.5-E10.5 or E13.5--15.5. Mice were euthanized at E18.5 and dam serum and brain, as well as fetuses, placentas and amniotic fluid, were harvested. For the YS-derived microglia progenitor ablation study, anti-CSF1R mAb (Clone AFS98, BioXCell, West Lebanon, NH, USA) or the rat IgG2a isotype control (Clone 2A3, BioXCell, West Lebanon, NH, USA) was injected intraperitoneally at E6.5 and E7.5 into the pregnant mice with or without subcutaneous inoculation of ZIKV (10^4^ PFU) at E6.5 or E8.5. Mice were euthanized at E11.5 and dam serum and brain, as well as YS, embryos and placenta were harvested.

Zika virus {#sec004}
----------

The infectious cDNA clone of ZIKV Puerto Rico strain PRVABC59 (rPRV) use used to rescue challenge virus according to our previous description \[[@pntd.0008413.ref024]\]. The parental PRVABC59 strain (GenBank number KU501215) was obtained from World Reference Center of Emerging Viruses and Arboviruses with five rounds passage on Vero cells. All procedures for handling ZIKV were approved by the Institutional Biosafety Committee.

Cell culture and infection {#sec005}
--------------------------

YS-derived progenitor cells were isolated from E10.5 pregnant mice as previously described with slight modifications \[[@pntd.0008413.ref025]\]. Briefly, the embryos were removed from the uterus and placed in a sterile dish with ice-cold phosphate-buffered saline (PBS) (Gibco, 21600--05, USA) containing 10% fetal bovine serum (FBS) (HyClone, SH30072.03, USA). The placenta was carefully removed from the embryo-encased YS, then the YS was gently separated from the embryo and placed in ice-cold PBS containing 10% FBS for dissociation. YSs from 5--6 embryos were pooled, passed through 18 gauge followed by 26 gauge needles several times, and then resuspended in PBS containing 0.25% collagenase (Gibco, 17101--015, USA) and 20% FBS. The mixture was incubated at 37°C for 20 minutes to generate a single-cell suspension. Cells were cultured in Dulbecco\'s modified Eagle\'s medium/Ham\'s F-12 (DMEM/F12) (Gibco, 11330--032, USA), supplemented with 10%FBS, IL-34 (10 ng/mL, R&D Systems, 5195-ML-101, USA), M-CSF(10 ng/mL, R&D Systems, 416-ML-010, USA) and 1% penicillin/streptomycin (Gibco, 15-140-122, USA); and incubated at 37°C with 5% CO~2~ \[[@pntd.0008413.ref026], [@pntd.0008413.ref027]\]~.~ For ZIKV infections, cells were treated with ZIKV at a multiplicity of infection of 1 Vero PFU/cell for 1 hour.

Quantitative Reverse Transcription PCR (RT-qPCR) {#sec006}
------------------------------------------------

Total RNA was extracted from tissues or liquid samples using the RNeasy Mini Kit (Qiagen, Hilden, Germany). ZIKV RNA levels were determined by the QuantiTect Probe RT-PCR Kit (Qiagen, Hilden, Germany) according to the manufacturer's manual on the LightCycler 480 System (Roche, Basel, Germany). The real-time PCR primers for ZIKV RNA detection were: ZIKV_1193F: 5′-CCGCTGCCCAACACAAG-3′ and ZIKV_1269R: 5′-CCACTAACGTTCTTTTGCAGACAT-3′ \[[@pntd.0008413.ref024]\]. The probe was 5′-FAM/AGCCTACCT/ZEN/TGACAAGCAATCAGACACTCAA/3IABkFQ-3' \[[@pntd.0008413.ref024]\]. The one-step RT-qPCR program was 30 minutes at 50°C for cDNA synthesis, 15 minutes at 95°C for initial heat activation, and 45 cycles of PCR (94°C for 15 seconds and 60°C for 1 minute). ZIKV RNA copies were determined relative to a standard curve produced using serial 10-fold dilutions of *in vitro* transcribed full-length ZIKV RNAs with a known concentration \[[@pntd.0008413.ref024]\].

Immunofluorescence imaging {#sec007}
--------------------------

Embryos were fixed in 4% paraformaldehyde (Sigma- Aldrich, P6148, USA)-PBS at 4°C for 1 h and immersed in 10%, 20% and 30% sucrose (Sigma- Aldrich, S7903, USA) until saturation. Tissues were embedded in OCT and fast frozen in a cold bath of methyl butane. Cryosections were cut at 20 μm. The YS was fixed in 4% paraformaldehyde-PBS at room temperature for 1 h and permeabilized in 100% methanol (Fisher Scientific, A412-4, USA) for 30 minutes at −20°C. Sections of the embryo heads and YSs were blocked in Tris Buffered Saline (TBS) (Sigma- Aldrich, T6664, USA) plus 10% normal goat serum (Jackson Immuno Research, 005-000-121, USA), 0.25% Triton-X-100 (Fisher, BP151-100, USA) and 2% bovine serum albumin (BSA) (Sigma Aldrich, A-4503, USA). Tissues were incubated with primary antibodies overnight at 4°C, followed by incubation with secondary antibodies in 0.25% Triton-X-100/TBS for 3 h at room temperature. Primary antibodies were included: rabbit antibodies against ZIKV E protein (1:200, Ab00230-23.0, Absolute Antibody, Oxford, UK); rat anti-F4/80 (1:200, ab6640, Abcam) for YS-derived microglia. Secondary antibodies were goat anti-rabbit IgG (1:1000, R37116, Invitrogen) conjugated with Alexa Fluor 488, and goat anti-Rat IgG (1:1000, A-11077, Invitrogen) with Alexa Fluor 568. DAPI (4',6-diamidino-2-phenylindole) was used to stain nuclei at a concentration of 1:5,000. Images were viewed and captured by a Nikon D-Eclipse C1si inverted confocal microscope with the EZ-C1 software v3.50 (Nikon, Japan).

Plaque assay {#sec008}
------------

Viral titers in the culture medium were determined by standard cytopathic effect-based plaque assay on Vero cells \[[@pntd.0008413.ref028]\]. Briefly, Vero cells (2 × 10^5^ per well) were seeded into 24-well plates. After 24 h post-seeding, viral samples were 10-fold serially diluted five times in Dulbecco\'s modified Eagle\'s medium (DMEM) (11965--092, Gibco, CA, USA). For each dilution, 100 μl sample was added to one well of the 24-well plate containing 90% confluent Vero cells. The infected cells were incubated at 37°C in 5% CO~2~ for 1 h and shacked every 15 mins to ensure even infection. After the incubation, 500 μl of methyl cellulose overlay was added to each well, and the plates were placed into the incubator at 37°C in 5% CO~2~. After four days incubation, methyl cellulose overlay was removed, and the plates were fixed with 3.7% formaldehyde at room temperature for 20 mins. Following fixation, the plates were stained with 1% crystal violet for 5 mins. Visible plaques were counted to calculate the viral titers (PFU/mL).

Statistical analysis {#sec009}
--------------------

All data were analyzed by GraphPad Prism 6 software and presented as the mean ± SD. Changes of maternal body weight were analyzed by two-way ANOVA with a Tukey post hoc test. Fetal viability data were analyzed with a Chi-square test. Viral RNA data and morphology measurements were analyzed by non-parametric Kruskal Wallis test with Dunn's multiple comparisons or one-way ANOVA with a Tukey post hoc test. A *P* value of \<0.05 was considered statistically significant.

Results {#sec010}
=======

Maternal ZIKV infection on E6.5--8.5 had a higher risk of fetal demise and brain malformation {#sec011}
---------------------------------------------------------------------------------------------

Since interferon type I receptor-deficient (Ifnar1^−/−^) mice are susceptible to ZIKV infection and disease \[[@pntd.0008413.ref023]\], we initially crossed female Ifnar1^−/−^ mice to Ifnar1^−/−^ or wild-type (WT) males, and subcutaneously infected them with cDNA clone-derived ZIKV (rPRV, an infectious clone of Puerto Rico strain PRVABC59 (24), 10^4^ PFU) on E6.5-E8.5, E9.5-E10.5, or E13.5--15.5 ([Fig 1A](#pntd.0008413.g001){ref-type="fig"}). These embryonic stages were chosen for their equivalence to the first and second trimesters of pregnancy in human \[[@pntd.0008413.ref029]\]. The miscarriage rate was significantly higher in Ifnar1^−/−^ females crossed to Ifnar1^−/−^ males than in those crossed to WT males (50% versus 23%) ([Fig 1B](#pntd.0008413.g001){ref-type="fig"}). Thus, the choice of using WT sires allowed us to generate enough embryos to address the critical issue of the role of microglia during ZIKV infection and embryonic brain development. More importantly, the 23% miscarriage rate (7 out of 31 pregnant dams did not have any fetus) of our Ifnar1^−/−^×WT model is closer to that of the nonhuman primates model, which has the miscarriage rate of 26% when infected at early gestation \[[@pntd.0008413.ref030]\].

![Gestation stage-dependent ZIKV vertical transmission in a mouse model.\
(A) Schematic depiction of ZIKV infection during pregnancy in the mouse model. Ifnar1^−/−^ female mice were crossed with WT males. Pregnant dams were infected with ZIKV at E6.5-E8.5, E9.5-E10.5 or E13.5--15.5. Samples were collected at E18.5. (B) Percentage of miscarriage dams or non-miscarriage dams after maternal infection with ZIKV on E6.5--8.5, E9.5--10.5 or E13.5--15.5. Female Ifnar1^−/−^ mice were crossed to Ifnar1^−/−^ males or WT males. The n above each bar indicates the number of dams per group. Data were assessed by Chi-square test, *P* \<0.0001. (C) Changes in maternal body weight over time in pregnant IFNAR1^-/-^ female mice infected by ZIKV at E6.5-E8.5, E9.5-E10.5 or E15.5. Data represent the mean ± SD. n = 6 in each group. Two-way ANOVA followed by a Tukey post hoc test. (D) Representative uteri and E18.5 fetuses from ZIKV-infected dams. One dam infected by ZIKV on E6.5 underwent miscarriage. Other dams generated grossly intact fetuses, but six of them underwent resorption (arrows in PRV on E6.5 to E9.5). One embryo did not have a well-formed eye structure (arrowhead, PRV on E6.5). Scale bar: 1 cm. (E) Percentage of resorbed or grossly intact fetuses after maternal infection with ZIKV on E6.5--8.5, E9.5--10.5 and E13.5--15.5. The n above each bar indicates the number of pups from 6--8 dams per group. Chi-square test, *P* \<0.0001. (F) Representative images of fetal brains (E18.5) from mock-infected, or dams with ZIKV infection on E6.5, E8.5, E10.5 and E15.5. Large black bars represent the average width of the fetal brain from uninfected dams. Scale bar: 2 mm. (G) Quantification of fetal brain width. Data represent the mean ± SD. n = 15 in mock, n = 21 in E6.5--8.5, n = 20 in E9.5--10.5, n = 23 in E15.5, 3--7 dams per group. Non-parametric Kruskal Wallis test with Dunn's multiple comparisons.](pntd.0008413.g001){#pntd.0008413.g001}

For assessment of ZIKV-infected fetal brains and clinical presentations, Ifnar1^−/−^ mice crossed with WT males were selected and dams were infected with rPRV (10^4^ PFU). The dams infected during early pregnancy (E6.5-E8.5) gained less weight than those infected at the later stages, or mock-infected ([Fig 1C](#pntd.0008413.g001){ref-type="fig"}), probably due to the higher rate of resorption and abnormal embryo development. Inspection of the fetuses on E18.5 revealed that ZIKV infection on E6.5-E8.5 resulted in miscarriage and a significantly higher rate of embryo resorption, compared to those in dams infected at later stages of pregnancy ([Fig 1D and 1E](#pntd.0008413.g001){ref-type="fig"}). The remaining grossly intact fetuses had much smaller brains than the controls ([Fig 1F and 1G](#pntd.0008413.g001){ref-type="fig"}). Furthermore, fetal brains from dams infected with ZIKV on E6.5-E8.5 had much higher viral loads detected by RT-qRCR ([Fig 2A](#pntd.0008413.g002){ref-type="fig"}), whereas both placenta and amniotic fluid had similar high viral loads when infected in all gestation stages ([Fig 2B and 2C](#pntd.0008413.g002){ref-type="fig"}). Moreover, no significantly higher viral loads were detected in the cortex and serum of dams subjected to early stage infection ([Fig 2D and 2E](#pntd.0008413.g002){ref-type="fig"}). Collectively, the results suggest that E6.5--8.5 is a critical stage for maternal ZIKV infection that leads to fetal demise and brain malformation in mice.

![ZIKV RNA loads in the mouse tissues.\
(A-E) ZIKV RNA loads in embryonic brains (n = 3 in mock, n = 8 in E6.5--8.5, n = 11 in E9.5--10.5, n = 9 in E15.5, 3--5 dams per group) (A), placenta (n = 3 in mock, n = 10 in E6.5--8.5, n = 8 in E9.5--10.5, n = 9 in E15.5, 3--4 dams per group) (B), amniotic fluid (n = 5 in mock, n = 10 in E6.5--8.5, n = 9 in E9.5--10.5, n = 8 in E15.5, 3--5 dams per group) (C), dam cortex (n = 3 in mock, n = 8 in E6.5--8.5, n = 7 in E9.5--10.5, n = 4 in E15.5) (D) and dam serum (n = 3 in mock, n = 8 in E6.5--8.5, n = 8 in E9.5--10.5, n = 4 in E15.5) (E), measured by RT-qPCR. The dashed line represents the limits of detection (LOD). Non-parametric Kruskal Wallis test with Dunn's multiple comparisons. \* *P* \<0.05, \*\* *P* \<0.01, \*\*\* *P* \<0.001 and \*\*\*\* *P* \<0.0001.](pntd.0008413.g002){#pntd.0008413.g002}

Yolk sac-derived microglial progenitors were susceptible to ZIKV infection *in vivo* {#sec012}
------------------------------------------------------------------------------------

Since the infection window E6.5--8.5 is within the critical stage of microglial development and migration, we asked whether murine YS microglia contribute to ZIKV dissemination to the fetal brain. Microglia arise predominantly from erythro-myeloid progenitors in the embryonic YS, which is an extra-embryonic membrane tissue with dense capillary networks ([Fig 3A and 3B](#pntd.0008413.g003){ref-type="fig"}) and the first site of hematopoiesis in both mice and humans \[[@pntd.0008413.ref031], [@pntd.0008413.ref032]\]. In mice, the YS-derived microglial progenitors appear at E7 to E8 and migrate to the brain as early as E9.5 after the blood vessels from the YS to the brain are established \[[@pntd.0008413.ref033]--[@pntd.0008413.ref035]\]. These microglial cells could be detected in the YS by immunostaining with antibodies targeting the microglia/macrophage lineage markers F4/80 ([Fig 3C](#pntd.0008413.g003){ref-type="fig"}) and CX3CR1 ([Fig 3D](#pntd.0008413.g003){ref-type="fig"}). Following ZIKV (the parental PRVABC59 strain, 10^6^ PFU) infection at E6.5, we found impaired blood vessel formation in the YS, and the number of F4/80^+^ cells in the YS was significantly reduced ([Fig 3B, 3C and 3E](#pntd.0008413.g003){ref-type="fig"}). The YS contained F4/80^+^ microglia co-stained with anti-ZIKV E protein, and many of these ZIKV-infected microglia were located linearly or within the vessel-like structure ([Fig 3C](#pntd.0008413.g003){ref-type="fig"} and [Fig 4A--4C](#pntd.0008413.g004){ref-type="fig"}). In the embryonic brain from ZIKV-infected dams ([Fig 5A](#pntd.0008413.g005){ref-type="fig"}), the number of F4/80^+^ cells was also decreased, and some F4/80^+^ microglia were found co-stained with anti-ZIKV E protein ([Fig 5B--5D](#pntd.0008413.g005){ref-type="fig"}). These data suggest that F4/80^+^ microglia may be able to carry ZIKV when they invade the fetal brain.

![Characterization of YS-derived microglia progenitors after ZIKV infection *in vivo*.\
(A) E11.5 uterus, YS, placenta and embryos from dams infected by ZIKV at E6.5. Two out of five embryos had undergone resorption (embryos 1 and 2), which were taken out from the uterus as the black arrow indicated, shown in (a). One of the other three embryos (embryo 5) was taken from the uterus, as shown in (b). Then, the embryo with the outside YS was carefully separated from the placenta, as shown in (c). In (d), the embryo was separated from the YS. They were connected by vessels. Scale bar: 5 mm. (B) Representative images of E11.5 YS from mock and ZIKV-infected dams on E6.5. Red arrow heads indicate blood vessels in the YS, white arrow indicates connecting vessels. (C) Representative confocal images of YS from mock and ZIKV-infected dam. Microglial progenitors (F4/80, red) co-stained (green) with antibodies against ZIKV E proteins are located linearly (arrow). Scale bar: 50 μm. (D) Representative confocal images of microglial cells (CX3CR1, red) in the E11.5 YS. (E) Quantitative analysis of the numbers of F4/80^+^ cells per area (n = 8 in mock from 5 dams, n = 11 in ZIKV from 6 dams), and the percentage of ZIKV infected F4/80^+^ cells in the YS from mock-infected and ZIKV-infected dam (n = 6 in mock from 5 dams, n = 6 in ZIKV from 5 dams). Unpaired t test, \*\* *P* \<0.01 and \*\*\*\* *P* \<0.0001.](pntd.0008413.g003){#pntd.0008413.g003}

![YS-derived microglia progenitors in the E11.5 YS.\
**(A-C)** Representative confocal images of various regions in the E11.5 YS from mock-infected and ZIKV-infected dam on E6.5. Microglial progenitors (F4/80, red) co-stained with antibodies against ZIKV E proteins (green) (arrow).](pntd.0008413.g004){#pntd.0008413.g004}

![YS-derived microglia progenitors in the E11.5 embryos brain.\
(A) Representative images of E11.5 embryo with the outside YS and placenta from mock-infected and ZIKV-infected dam on E6.5. (B and C) Representative confocal images of embryonic brains from mock and ZIKV-infected dams. Microglial progenitors (F4/80, red) co-stained with antibodies against ZIKV E proteins (green) (arrow). (D) Quantitative analysis of the numbers of F4/80^+^ cells per area (n = 5 in mock from 5 dams, n = 5 in ZIKV from 5 dams), and the percentage of ZIKV infected F4/80^+^ cells in the embryonic brain from mock-infected and ZIKV-infected dam (n = 5 in mock from 5 dams, n = 5 in ZIKV from 3 dams). Unpaired t test, \*\* *P* \<0.01 and \*\*\*\* *P* \<0.0001.](pntd.0008413.g005){#pntd.0008413.g005}

Yolk sac-derived microglial progenitors were susceptible to ZIKV infection *in vitro* {#sec013}
-------------------------------------------------------------------------------------

To confirm that YS-derived microglial progenitors are susceptible to ZIKV infection, we isolated microglial progenitors from the YS on E10.5 ([Fig 6A](#pntd.0008413.g006){ref-type="fig"}) and infected with ZIKV for one hour. Immunostaining results showed that over 99% of the cells were F4/80^+^ one week after culture, indicating they were microglia ([Fig 6B and 6C](#pntd.0008413.g006){ref-type="fig"}). The co-localization of F4/80 with anti-ZIKV antibody demonstrated that cultured microglial progenitors from the YS were susceptible to ZIKV infection ([Fig 6B](#pntd.0008413.g006){ref-type="fig"}). The infected microglia progenitors were able to produce progeny viruses and release them to the culture medium ([Fig 6D](#pntd.0008413.g006){ref-type="fig"}). Further quantitative analysis showed that less than 1% of F4/80^+^ cells were co-stained with anti-ZIKV antibody one week after infection ([Fig 6C](#pntd.0008413.g006){ref-type="fig"}). These data suggest that F4/80^+^ microglia may be able to disseminate the viral infection when they invade the fetal brain.

![Characterization of YS-derived microglia progenitors after ZIKV infection *in vitro*.\
(A) Isolation of microglial progenitors from YS on E10.5. The YS tissue was isolated into single-cell suspension via mechanical dissociation and chemical digestion (left panels). Most of the cells touched the bottom of the plate three days after culture (right panels). (B) Representative confocal images of cultured YS-derived microglial progenitors expressing F4/80 (red) from control (top row) or those infected by ZIKV (bottom row). ZIKV was detected by antibodies against the E protein (green). Insets are enlarged to the right, showing cells co-labeled with F4/80 marker and ZIKV E proteins (yellow). (C) Quantitative analysis of the percentage of F4/80^+^ cells after one week culture (n = 6 in mock from 5 dams, n = 8 in ZIKV from 4 dams), and the percentage of ZIKV-infected F4/80^+^ cells after one week culture (n = 6 in mock from 5 dams, n = 8 in ZIKV from 4 dams). Unpaired t test, \*\*\* *P* \<0.001. (D) Plaque assay of the culture medium collected from ZIKV-infected YS-derived microglia progenitors. Data were present as the mean ± SD (n = 4 from 2 dams).](pntd.0008413.g006){#pntd.0008413.g006}

Ablation of microglial progenitors reduced the viral load in embryonic mouse brains {#sec014}
-----------------------------------------------------------------------------------

Microglial development and maintenance require the colony stimulating factor 1 receptor (CSF1R) \[[@pntd.0008413.ref036]\]. To determine whether YS-derived microglial progenitors contribute to ZIKV vertical transmission from mother to fetal brain, anti-CSF1R antibody was injected intraperitoneally at E6.5 and E7.5 into the pregnant mice to ablate the microglial lineage \[[@pntd.0008413.ref037]\] ([Fig 7A](#pntd.0008413.g007){ref-type="fig"}). As shown in [Fig 7B and 7C](#pntd.0008413.g007){ref-type="fig"}, two days of anti-CSF1R treatment almost completely depleted microglial progenitors and microglial cells in the YS on E11.5. The ablation efficiency was 99.4% confirmed by staining with the F4/80 marker ([Fig 7C](#pntd.0008413.g007){ref-type="fig"}), which was consistent with the 99% ablation efficiency previously reported by others \[[@pntd.0008413.ref037], [@pntd.0008413.ref038]\]. Since the microglia in the fetal brain are solely derived from YS-derived microglia progenitors, as expected, the number of F4/80^+^ cells in the embryonic brain was also significantly decreased by 90% ([Fig 7B and 7D](#pntd.0008413.g007){ref-type="fig"}). We then carried out the experiment with pregnant mice receiving the anti-CSF1R antibody at E6.5 and E7.5, accompanied by ZIKV infection within the window of E6.5-E8.5 ([Fig 7A](#pntd.0008413.g007){ref-type="fig"}). Interestingly, depletion of microglial progenitors reduced ZIKV-caused fetal demise ([Fig 7E](#pntd.0008413.g007){ref-type="fig"}). ZIKV loads in the YS, embryo brains and hearts were significantly reduced in animals with microglial progenitors depleted ([Fig 8A--8C](#pntd.0008413.g008){ref-type="fig"}), despite the high viral loads found in the dam's serum and cortex as well as placenta ([Fig 8D--8F](#pntd.0008413.g008){ref-type="fig"}). These results indicate that YS microglial progenitors may act as "Trojan horses" to transport Zika virus from the mother to the fetal brain.

![Depletion of YS-derived microglia progenitors after ZIKV maternal infection.\
(A) Illustration of the experimental design. Anti-CSF1R antibody was injected intraperitoneally at E6.5 and E7.5 into pregnant mice accompanied by ZIKV subcutaneous inoculation at E6.5 or E8.5. Samples were collected at E11.5. (B) Representative confocal images of microglial cells (F4/80, red) in the E11.5 YS and the E11.5 embryonic brains with or without anti-CSF1R treatments. Insets are enlarged to the right. Scale bar: 50 μm. (C) Quantitative analysis of the numbers of F4/80^+^ cells per area in the YS (n = 7 in mock from 4 dams, n = 14 in ZIKV from 4 dams). Unpaired t test, \*\*\*\* *P* \<0.0001. (D) Quantitative analysis of the numbers of F4/80^+^ cells per area in the embryonic brain (n = 5 in mock from 5 dams, n = 7 in ZIKV from 3 dams). Unpaired t test, \*\*\*\* *P* \<0.0001. (E) Percentage of resorbed or grossly intact fetuses after maternal infection with ZIKV on E6.5--8.5 with or without YS-derived microglia progenitors ablation. The n above each bar indicates the number of pups from 2--7 dams per group. Chi-square test, *P* \<0.0001.](pntd.0008413.g007){#pntd.0008413.g007}

![Viral burden after ZIKV maternal infection with depletion of YS-derived microglia progenitors.\
(A-F**)** ZIKV RNA loads in the YS (n = 3 in mock, n = 19 in rPRV, n = 3 in rPRV+IgG, n = 9 in rPRV+anti-CSFR1R, 2--7 dams per group) (A), embryonic brain (n = 3 in mock, n = 17 in rPRV, n = 3 in rPRV+IgG, n = 10 in rPRV+anti-CSFR1R, 2--6 dams per group) (B), embryonic hearts (n = 3 in mock, n = 10 in rPRV, n = 3 in rPRV+IgG, n = 6 in rPRV+anti-CSFR1R, 2--5 dams per group) (C), dam cortex (n = 3 in mock, n = 7 in rPRV, n = 2 in rPRV+IgG, n = 3 in rPRV+anti-CSFR1R, 2--7 dams per group) (D), dam serum (n = 3 in mock, n = 7 in rPRV, n = 2 in rPRV+IgG, n = 3 in rPRV+anti-CSFR1R, 2--7 dams per group) (E), and the placenta (n = 3 in mock, n = 10 in rPRV, n = 3 in rPRV+IgG, n = 8 in rPRV+anti-CSFR1R, 2--3 dams per group) (F), measured by RT-qPCR. One-way ANOVA with a Tukey post hoc test. The dashed line represents the LOD. \* *P* \<0.05, \*\* *P* \<0.01, \*\*\* *P* \<0.001 and \*\*\*\* *P* \<0.0001.](pntd.0008413.g008){#pntd.0008413.g008}

Discussion {#sec015}
==========

In this study, we carefully examined the teratogenic effect of ZIKV infection during different stages of pregnancy in a mouse model. The higher risk of ZIKV-mediated abnormal embryonic development during a defined window of pregnancy led us to investigate the role of microglia in the fetal brain dissemination of ZIKV. Our data suggest that YS-derived microglia may serve as a "Trojan horse" to disseminate ZIKV into embryo brains.

In our ZIKV vertical transmission model, we crossed Ifnar1^−/−^ female mice with WT male mice, and found that 77% of the pregnant mice produced Ifnar1^+/−^ fetuses when examined on E18.5 after ZIKV infection. On the other hand, only 50% of Ifnar1^−/−^ female mice, when crossed with Ifnar1^−/−^ males, yielded live Ifnar1^−/−^ fetus on E18.5, indicating a higher miscarriage rate occurred in Ifnar1^−/−^ females when crossed with Ifnar1^−/−^ males. Interestingly, however, the Ifnar1^−/−^ fetuses exhibited better developmental outcomes than the Ifnar1^+/−^ fetuses (from Ifnar1^−/−^×Ifnar1^−/−^: 90.0%, or 108 grossly intact fetuses among total 120 fetuses from 18 dams; from Ifnar1^−/−^×WT: 71.9%, or 128 grossly intact fetuses among total 178 fetuses from 24 dams). This result is similar to the findings of Yockey et al. \[[@pntd.0008413.ref039]\] in terms of fetal survival. Assessing the outcomes of fetuses in the Ifnar1^−/−^×WT model after ZIKV maternal infection, we found that E6.5-E8.5 was a critical stage which led to the increased rate of ZIKV-associated fetal demise and microcephaly. Following infection in later stage, ZIKV was less able to gain access to the fetal brain. These findings are consistent with studies in pregnant women, which have shown that ZIKV infection at early gestational stages increases the risk of miscarriage and fetal brain malformation \[[@pntd.0008413.ref001], [@pntd.0008413.ref002]\]. Similar results have also been reported in several studies of ZIKV vertical transmission using mouse models \[[@pntd.0008413.ref006], [@pntd.0008413.ref009], [@pntd.0008413.ref010]\]. On the other hand, some groups have shown that maternal infection at E9-E14 may also lead to a high rate of abortion, significant intrauterine growth restriction and smaller fetal brains \[[@pntd.0008413.ref007], [@pntd.0008413.ref008], [@pntd.0008413.ref040], [@pntd.0008413.ref041]\]. Such a discrepancy may be attributed to different infection routes (intrauterine, intravenous or intraperitoneal), mouse genetic background, viral strains and infection doses. Particularly, intrauterine infection bypasses most of the host defense mechanisms, which likely affects the outcome of fetuses.

The mechanisms of the gestational age-dependent variation in fetal damage following ZIKV vertical transmission have not been well elucidated. The placenta is the primary barrier between the mother and the fetus throughout pregnancy \[[@pntd.0008413.ref042]\]. A fully functional placenta is formed on E10.5 in mice and at the end of the first trimester in humans \[[@pntd.0008413.ref043]\]. ZIKV can traffic across the placenta to reach the fetus by infecting placental cells (villous trophoblasts, fibroblasts, Hofbauer cells and fetal endothelial cells) and compromising the placental barrier \[[@pntd.0008413.ref006], [@pntd.0008413.ref044]--[@pntd.0008413.ref049]\]. Besides the transplacental route of ZIKV vertical transmission, Tabata et al. also proposed a paraplacental route, in which ZIKV spreads from the parietal decidua to amniochorionic membranes \[[@pntd.0008413.ref047]\]. Viral progeny released into the amniotic fluid may infect vulnerable cells in the fetal skin \[[@pntd.0008413.ref050], [@pntd.0008413.ref051]\]. In our studies, equally high ZIKV RNA loads were detected in both the placenta and amniotic fluid following infection in all gestation stages. However, significantly higher RNA loads in the fetal brain were only found after ZIKV infection at E6.5-E8.5 as compared to the later stages. This infection window precedes placenta formation and is right within the critical period of microglial development, suggesting a role of microglia in ZIKV vertical transmission before placenta formation.

Mouse microglia originate from YS erythro-myeloid progenitors around E7 to E8, and begin to colonize the brain at E9.5 to E10.5 after the circulation system to the brain is established \[[@pntd.0008413.ref033]--[@pntd.0008413.ref035], [@pntd.0008413.ref052], [@pntd.0008413.ref053]\]. In humans, the size of the YS progressively increases from 5 to 10 weeks of gestation, after which it gradually decreases and disappears after 12^th^ week of gestation (near the end of the first trimester) \[[@pntd.0008413.ref054]\]. YS-derived microglia expand in the central nervous system and maintain themselves via local proliferation throughout life to become the primary innate immune defenders of the brain \[[@pntd.0008413.ref016], [@pntd.0008413.ref032], [@pntd.0008413.ref053]\]. Both brain and hiPSCs-derived macrophages/microglia are susceptible to ZIKV infection \[[@pntd.0008413.ref020], [@pntd.0008413.ref055]--[@pntd.0008413.ref058]\]. In our study, we observed for the first time that mouse YS-derived microglia progenitors can be infected by ZIKV. Additionally, ZIKV-infected microglia entered the vessels in the YS. It is thus possible that the infected YS-derived progenitor cells transport ZIKV from mother to embryo, and spread the infection in the brain after migration.

Here, by using the anti-CSF1R antibody to ablate the microglia progenitors that originate from the YS, we found that ZIKV RNA loads significantly decreased in the YS, the embryonic brain and the heart without affecting the viral loads in the dam tissues. Altogether, these results suggest that YS microglial progenitors serve as "Trojan horses", contributing to the ZIKV transfer from the mother to the fetal brain before the complete formation of placenta. An alternative explanation could be that the reduction of ZIKV viral load in the embryo brains after microglia ablation was simply due to the loss of a ZIKV-tropic cell type in the brain. However, this seems unlikely because the degree of viral reduction in embryo brains did not match the extent of microglia depletion. It should be noted that the depletion of YS-derived microglia progenitors did not completely eliminate ZIKV loads in the YS and the embryonic brain. This may be due to that anti-CSF1R-mediated ablation cannot completely remove YS microglia progenitors. Alternatively, other progenitor cells in the YS may also act as transporters during migration if they are susceptible to ZIKV infection \[[@pntd.0008413.ref059]\].

Microglia, besides their immune defensive function, also play an important role in brain development and behavior function \[[@pntd.0008413.ref016], [@pntd.0008413.ref037], [@pntd.0008413.ref060]--[@pntd.0008413.ref062]\]. Microglia can modulate normal embryonic brain development by affecting the proliferation of NS/PCs, particularly during the peak of NS/PCs proliferation and differentiation \[[@pntd.0008413.ref060]\]. Thus, ablation of microglia could, in theory, reduce the number of NS/PCs and consequently the ZIKV RNA load. However, microglia start to migrate into embryo brains at E9-10, and the effect of microglia ablation on NS/PCs proliferation is minimal by the time we collected the embryos (E11.5) \[[@pntd.0008413.ref018]\]. Thus, the reduced numbers of microglia and possibly NS/PCs are unlikely to count for the degree of ZIKV RNA reduction detected in the E11.5 embryo brains. On the other hand, anti-CSF1R mediates only a temporary depletion of the YS and brain microglia, which will gradually come back after E14.5 and repopulate completely by the first postnatal weeks \[[@pntd.0008413.ref037]\]. Although not causing significant brain malformation, the microglia ablation during early embryonic stages could induce long-lasting effects on offspring, such as altering the wiring of forebrain circuits and causing hyperactivity or anxiolytic-like behavioral problems \[[@pntd.0008413.ref037], [@pntd.0008413.ref062]\]. As anti-CSF1R efficiently depletes microglia in both the YS and the embryonic brain, the inflammatory status of microglia per se may have minimal if any effect on brain development in ZIKV-infected embryos. It will be interesting to determine whether anti-CSF1R could directly reduce ZIKV infection/replication in microglia. Easley-Neal et al. \[[@pntd.0008413.ref063]\] reported that these antibodies could cross the blood-brain barrier to exert their function through intraperitoneal injection in adult mice. Our data show a lack of changes of ZIKV RNA in the dam brain 3--5 days after anti-CSF1R antibodies treatment ([Fig 4I](#pntd.0008413.g004){ref-type="fig"}), indicating that the direct antiviral effect of anti-CSF1R unlikely occurs in this mouse system.

In terms of the effect of microglia depletion on viral infection, Funk et al. demonstrated that CSF1R inhibition-mediated ablation increased WNV infection in adult mice \[[@pntd.0008413.ref064]\]. We found that microglial depletion decreases ZIKV infection in the embryonic brain. This discrepancy is most likely attributed to the different populations of microglia with different functional maturation from early developmental (embryo) vs. fully matured (adult) brains \[[@pntd.0008413.ref065]\]. Before E11.5, the microglia in the fetal brain are solely derived from the YS erythro-myeloid progenitors \[[@pntd.0008413.ref018]\]. In adult mice, monocyte may infiltrate to the brain under inflammation \[[@pntd.0008413.ref064], [@pntd.0008413.ref066], [@pntd.0008413.ref067]\]. Monocyte generation begins after E11.5 from the hematopoietic stem cells in the fetal liver and later in the bone marrow \[[@pntd.0008413.ref068], [@pntd.0008413.ref069]\]. Thus, the E11.5 embryonic brain in our study contains only microglia originated and migrated from the YS; whereas the fully developed adult brain contains both resident microglia and infiltrated monocytes derived from the bone marrow under certain circumstances. The latter, reported by Funk et al. \[[@pntd.0008413.ref064]\], also contributes to the virologic control in the CNS.

Modeling neurotropic virus infection is challenging. To mimic the dynamic interaction between host and virus in human, several animal models have been used. However, the host responses to viral infection may not be fully shared across species, and there may be species-specific differences in viral susceptibility. For example, immunocompetent mice are rather resistant to ZIKV infection because ZIKV NS5 is unable to degrade the antiviral molecule STAT2 in mice \[[@pntd.0008413.ref070], [@pntd.0008413.ref071]\]. Genetic engineering to remove type I or/and type II IFN signaling yielded several mouse models that are susceptible to ZIKV disease. In our Ifnar1^−/−^×WT mouse model, the miscarriage rate was 23%, which was close to the nonhuman primates model reported by Dudley et al. \[[@pntd.0008413.ref030]\]. The hSTAT2 knock-in immunocompetent mouse model ensues the host immune response, so it is more closely reflects the human disease \[[@pntd.0008413.ref072]\]. However, mice infected with ZIKV do not show Guillain-Barré syndrome as in human \[[@pntd.0008413.ref070]\]. In addition, the structure of the mouse placenta is different from that of humans, which may require higher maternal viremia \[[@pntd.0008413.ref070], [@pntd.0008413.ref073]\]. Regarding the non-human primate models, several groups reported that ZIKV infection during early pregnancy resulted in fetal death and exhibited many features of congenital Zika syndrome in human \[[@pntd.0008413.ref030], [@pntd.0008413.ref074], [@pntd.0008413.ref075]\]. However, non-human primate models are very costly, which limits the number of animals studied. In any case, further studies in an immunocompetent mouse model such as the recently developed hSTAT2 knock-in mice or in the non-human primate model are warranted to confirm the role of yolk sac microglia as a general mechanism mediating ZIKV dissemination into embryonic brains.

10.1371/journal.pntd.0008413.r001
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Dear Dr. Wu,

Thank you very much for submitting your manuscript \"Role of yolk sac microglia in vertical transmission of Zika virus

from mother to fetal brain\" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers\' comments.

In general the reviewers of this manuscript liked this manuscript but have identified several important concerns that need to be addressed prior to further consideration of this submission. I ask that you also give consideration to comments from the reviewers regarding data interpretation and address some of the potential caveats that have been highlighted.

Further, we would like to apologize for the long review process for this submission. It took some time to identify reviewers for this manuscript.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers\' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

\[1\] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

\[2\] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.

Sincerely,

Michael R Holbrook, PhD

Guest Editor
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Rebecca Rico-Hesse

Deputy Editor
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\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

In general the reviewers of this manuscript liked this manuscript but have identified several important concerns that need to be addressed prior to further consideration of this submission. I ask that you also give consideration to comments from the reviewers regarding data interpretation and address some of the potential caveats that have been highlighted.

Further, I would like to apologize for the long review process for this submission. It took some time to identify reviewers for this manuscript.

Reviewer\'s Responses to Questions

**Key Review Criteria Required for Acceptance?**

As you describe the new analyses required for acceptance, please consider the following:

**Methods**

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#1: We have no concerns about the methods used in this study. We would like to encourage the authors to measure infectious virus and not just viral RNA as this does not confirm whether use of the monoclonal antibody actually prevents virus replication in tissues.

Reviewer \#2: -The data in figure 1B are very interesting, though the experiment is under-powered with only an n of 4. This experiment should be repeated. To what do the authors attribute the differences in maternal weight gain following early term infection vs late term infection? Importantly, does the virologic status of the dam change depending on the gestational timepoint of infection? These data would clarify the authors' overall findings considerably and bolster this study's value as a reference for the field.

-While the images in Figure 2 are generally of high quality, the reliance on representative images with no quantification diminishes enthusiasm for the study. Quantification of the numbers of infected F4/80+ cells detected per unit area in yolk sac and fetal brain should be provided to establish the level of variability and overall generalizable nature of these findings.

-In Figure 2C, how were the imaged structures determined to be blood vessels? Why do F4/80+ cells appear to permeate the yolk sack in 2B, but seem concentrated in a single blood vessel in 2C. The differences in cellularity between these two images is confusing. Again, more robust quantification and explanation of analytical methods is necessary to interpret these data.

-A more quantitative assessment of viral infection in YS microglial progenitors is warranted in Figure 2E. Are these cells productively infected, producing progeny virus? What is the time course of viral burden and shedding? Multistep growth curve or similar analyses would be helpful to more robustly profile the virologic profile of these cells.

-The efficiency of depletion of microglia in YS and fetal brain following antibody administration to the pregnant dam is somewhat surprising. The authors should include quantification of F4/80+ cells per unit area across multiple mice in figures 3B and 3C to establish the consistency and reproducibility of this depletion.

-Were microglia also depleted in the brains of dams treated with anti-CSFR1 antibodies? While in theory, perhaps, these antibodies would not cross the BBB, this should be experimentally confirmed. If changes to maternal microglial numbers are discovered, these should be accounted for in the interpretation of the authors' results.

Reviewer \#3: Please include more information on the sample size for each experiment.

Additional information on how representative the images shown are and if there is any way to quantify the level of ablation among the different animals it would strengthen they results.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: Result are clearly presented with exceptionally good images.

Reviewer \#2: - The rationale for reporting miscarriage rates in Ifnar1xWT vs. Ifnar1xIfnar 1 crosses (Figure S1) is unclear. Are the authors justifying why they chose to use WT sires for their main studies? At present, these data do not seem relevant and need further discussion. Moreover, these data are contradictory to those reported by Yockey et al (PMID 29305462) who reported worse outcomes in Ifnar1-heterozygous embryos compared to Ifnar1-deficient embryos following ZIKV infection. The authors should discuss this discrepancy.

-Similar to above -- what is the purpose of Figure S2? Are the authors justifying using an infectious clone in their study? These data should be more well integrated into the paper or removed.

-The statistical comparisons in Figures 1G-I appear inconsistent. Some comparisons with smaller effect sizes and higher variance have higher p values than other comparisons with larger effect sizes and less variance. Which test was used for these graphs, specifically? For Figure 1I, why are values reported below the limit of detection?

Reviewer \#3: Fig 2B -- Add a scale bare to the zoomed images.

Fig 2 -- Please add the number of embryo brains processed that showed similar data.

Fig 3 -- How consistent was the ablation of YS microglia? Only a single micrograph is shown, is this representative of X embryos, or did some embryos retain higher levels of staining? Is there any way to quantify (RT-PCR in embryo brain?)?

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: The fundamental missing piece of data that results in an incomplete story is whether treatment of dams with anti-CSFIR reverses the detrimental effects of ZIKV on offspring viability (as shown in Figure 1). It is never reported whether by reducing ZIKV in the brain microglia reverses the adverse effects of ZIKV on development or if that is caused by something else (e.g., immunopathology). Along those lines, the authors also do not show the impact of anti-CSFIR alone (without ZIKV) on microglia and adverse outcomes. Finally, there are no data pertaining to microglia activation, only co staining for ZIKV. Does anti-CSFIR reduce not only microglia infection but activation (i.e., neuroinflammation)?

Reviewer \#2: -Funk and colleagues recently reported decreased virologic control of WNV-infected mice treated with a CSFR1 antagonist (PMID 30704498). In general, more detailed discussion of previous studies demonstrating the anti-viral capacity of microglia in adults using similar depletion strategies should be discussed, as they contrast somewhat with the authors findings in fetuses in the current study.

-A major issue of concern is the use of immunodeficient Ifnar-/- animals as the basis for in vivo phenotypes. IFN-deficient mice exhibit greatly increased viremia and expanded viral tropism that may confound the ability to truly map routes of entry into the fetal CNS as they occur naturally. This issue is one faced by the entire field and not solely a problem with the current manuscript, but some circumspection in the interpretations of the authors' findings is warranted in the discussion. While likely beyond the scope of the current manuscript, establishing similar phenotypes in an immunocompetent mouse model (such as the recently developed hSTAT2 knockin mouse) or even in NHP models will be needed to confirm the authors' findings. The authors should elaborate on these points in the discussion.

-While an intriguing hypothesis, the authors do not currently have sufficient evidence to establish any role for microglial progenitors in "vertical transmission." Any virus present in the fetal YS would in theory already be "transmitted" from the infected dam. Instead, the authors posit a possible route of viral dissemination to the fetal brain, but even this possibility will need more careful experimentation to establish. The authors findings could simply arise from a depletion of a tropic cell type from the fetal brain, thereby diminishing a major replicative niche for the virus, irrespective of the movement of infected cells from YS to fetal brain. The authors should be more circumspect in their interpretation of the findings in figure 3, or otherwise perform more careful time course experiments in which YS microglia are depleted either before or after populating the fetal brain.

Reviewer \#3: I assume ablation of microglial progenitor cells during this early time of development has severe consequences to normal embryo brain development. Please discuss how this alteration in brain development could alter ZIKV replication in the brain. What would happen if you ablated the cells and directly inoculated the brain? Would there be less permissive cells there? To further establish these cells are a "Trojan horse" for the virus to get across the maternal-fetal interface, can you quantify virus levels in non-brain tissue of the embryos? Is it similarly decreased or is it specific for virus levels in the brain?

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: n/a

Reviewer \#2: -For the n values for embryos throughout the manuscript, the number of unique litters should also be reported.

Reviewer \#3: Fig 1B -- Figure is labeled "WT", but I think it is showing "mock" infected data?

Fig 2A -- The Figure legend description of the pictures is somewhat hard to follow. There are several arrows in the picture and two things circled. It may help to number each embryo. Alternatively, if the picture is shown to demonstrate the distinct location of the yolk sac versus the embryo you may want to just include a cartoon and last picture in the series.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: Overall, i like the direction of the studies and the novelty of yolk sac derived microglia. How this impacts adverse outcomes in the fetus as well as microglia activation are logical, yet missing experiments in the current manuscript.

Reviewer \#2: In this study, Xu et al present intriguing evidence for the importance of gestational age on the dissemination of ZIKV to the fetal brain, with some exploration of possible roles for yolk sac derived microglia. The authors' systematic characterization of the virologic outcomes of maternal ZIKV infection at different stages of gestation is highly informative and an important addition to the existing literature. While the authors convincingly demonstrate that fetal microglial progenitors are tropic for ZIKV and contribute to viral burden in the fetal brain, the purported roles for these cells in transmission/dissemination are somewhat prematurely drawn. While this study will likely be of broad interest, some improvements are warranted before publication.

Reviewer \#3: This study by Xu et al is characterizing the role of yolk sac microglial progenitor cells in transporting Zika virus across the maternal placenta to infect the developing embryo. Ablation of the yolk sac microglial progenitor cells reduced ZIKV in the embryonic brain, although did not eliminate it. The paper is well written and straight forward. To enhance the conclusions of the study additional discussion about how ablation of the YS microglial progenitor cells will alter the brain structure is warranted.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosntds/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [https://pacev2.apexcovantage.com. PACE](https://pacev2.apexcovantage.com. PACE) helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Data Requirements:

Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <https://journals.plos.org/plosntds/s/submission-guidelines#loc-methods>
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12 May 2020

Dear Dr. Wu,

Thank you very much for submitting your manuscript \"Role of microglia in the dissemination of Zika virus

from mother to fetal brain\" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Please move supplemental figures to the main text. PLoS NTDs does not limit the number of figures so it is best to include as much data as is reasonable in the primary publication. Some of the data provided in supplemental material is important for interpretation of you data.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.  

When you are ready to resubmit, please upload the following:

\[1\] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript. 

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

\[2\] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.

Sincerely,

Michael R Holbrook, PhD

Associate Editor

PLOS Neglected Tropical Diseases

Rebecca Rico-Hesse

Deputy Editor

PLOS Neglected Tropical Diseases

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Please move supplemental figures to the main text. PLoS NTDs does not limit the number of figures so it is best to include as much data as is reasonable in the primary publication. Some of the data provided in supplemental material is important for interpretation of you data.

Reviewer\'s Responses to Questions

**Key Review Criteria Required for Acceptance?**

As you describe the new analyses required for acceptance, please consider the following:

**Methods**

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#1: • The authors have cultured Yolk sac microglia-progenitors, infected them with ZIKV, and then performed a plaque assay. We had intended that the authors would have use a plaque assay or similar measure of infectious virus to evaluate the infectious virus in collected tissue, for example in Figure 1G-I, and Figure 4F-J. In figure 4 specifically, this would allow the authors to show that the Anti-CSFR1 antibody decreased the amount of infectious zika virus in the embryonic brain. The plaque assay experiment in Figure S3 may fit better incorporated into figure 3.

Reviewer \#2: (No Response)

Reviewer \#3: They have added additional information on sample size, and in some cases increased samples size. No concerns.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: • The authors' additional experiment (Figure S4A) have addressed our main concern here, and have shown that depletion of the yolk sac progenitors with the anti-CSF1R antibody reduces the fetal demise during zika infection. This figure seems vital to the overall narrative of the manuscript, and we would suggest adding it to figure 4.

Reviewer \#2: (No Response)

Reviewer \#3: The new version of the figures is easier to understand.

The current figures were all blurry after download - but probably just a conversion problem.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: fine

Reviewer \#2: (No Response)

Reviewer \#3: The conclusions are well defined and address the data as well the the public health relevance.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

Reviewer \#3: Accept

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: Move data from supplemental information to main figures in text. Also, measuring infectious virus in tissues is needed.

Reviewer \#2: (No Response)

Reviewer \#3: All concerns were addressed.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosntds/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [https://pacev2.apexcovantage.com. PACE](https://pacev2.apexcovantage.com. PACE) helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Data Requirements:

Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosntds/s/submission-guidelines#loc-materials-and-methods>
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22 May 2020

Dear Dr. Wu,

We are pleased to inform you that your manuscript \'Role of microglia in the dissemination of Zika virus

from mother to fetal brain\' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Michael R Holbrook, PhD

Associate Editor

PLOS Neglected Tropical Diseases

Rebecca Rico-Hesse

Deputy Editor

PLOS Neglected Tropical Diseases
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26 Jun 2020

Dear Dr. Wu,

We are delighted to inform you that your manuscript, \"Role of microglia in the dissemination of Zika virus from mother to fetal brain ,\" has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

[^1]: The authors have declared no competing financial interests.
